Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
Bert van Meurs, Chief Business Leader Image Guided Therapy and Member of the Executive Committee at Royal Philips, shared on LinkedIn:
”New late-breaking results from the iMODERN trial, presented at TCT 2025, bring important clarity for heart attack patients with multi-vessel disease.
This global study confirms that treating additional lesions during the initial procedure is just as safe as waiting to stage treatment, giving clinicians more flexibility to tailor care to each patient’s needs.
Complementary findings from the ILIAS ANOCA study also highlight the value of physiology-guided assessment and personalized therapy for patients with angina but no obstructive coronary arteries, resulting in sustained improvements in quality of life.
I’m proud that Philips solutions supported both of these impactful studies.
Together with our clinical partners, we’re helping advance evidence-based, individualized cardiovascular care for patients worldwide.”
Read the full announcement here.
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 13:58Peter Bou Dib: How Factor IX Transformed Hemophilia B Treatment
-
Jun 26, 2026, 13:49Raghavendra Rao: The Surprising Link Between Chronic Venous Insufficiency and Falls
-
Jun 26, 2026, 13:40Caylynn Carls: Why Genetic Counseling Matters in Hemophilia Treatment
-
Jun 26, 2026, 13:25Ángel Cabrera: Clotting Disorders Behind Heavy Menstrual Bleeding
-
Jun 26, 2026, 13:02Turid Kjellevold: The Critical Role of Timely Hemostasis Testing
-
Jun 26, 2026, 10:59Wolfgang Miesbach: How Clonal Hematopoiesis May Explain Age-Related Mitochondrial Mutations
-
Jun 26, 2026, 10:52Chinua Onyebuchi: The Future of Stroke Care in Africa Lies in Strong Health Systems
-
Jun 26, 2026, 10:35Habtamu Milkias Wolde: New Insights into Stroke and Traumatic Brain Injury from Global Burden of Disease Data
-
Jun 26, 2026, 10:19Rytis Masiliūnas: Atrial Fibrillation and Stroke Care Disparities Across the Baltic Region